Risk Markers and Appropriate Implantable Defibrillator Therapy in Hypertrophic Cardiomyopathy

Peter Magnusson1,2, Fredrik Gadler1, Per Liv2

  • 1Cardiology Research Unit, Department of Medicine, Karolinska Institutet, Karolinska University Hospital/Solna, Stockholm, Sweden.

Insights

Implantable cardioverter defibrillator (ICD) therapy effectively treats ventricular arrhythmias in hypertrophic cardiomyopathy (HCM). A history of atrial fibrillation (AF) or reduced ejection fraction (EF) <50% are key risk markers for appropriate ICD therapy in HCM patients.

Area of Science:

  • Cardiology
  • Electrophysiology
  • Genetics

Background:

  • Sudden cardiac death (SCD) risk stratification in hypertrophic cardiomyopathy (HCM) traditionally relies on specialized centers.
  • Evaluating risk markers in unselected, nationwide HCM cohorts is crucial for broader clinical application.

Purpose of the Study:

  • To identify and evaluate risk markers for appropriate implantable cardioverter defibrillator (ICD) therapy in a nationwide HCM cohort.
  • To assess the effectiveness of ICD therapy in managing ventricular arrhythmias in HCM.

Main Methods:

  • Utilized data from the Swedish ICD Registry and Patient Register, including retrieved medical records.
  • Analyzed risk markers for ventricular arrhythmias leading to appropriate ICD therapy using Cox proportional hazard ratios (HR).
  • Included 321 HCM patients with ICDs, followed for a mean of 5.4 years.

Main Results:

  • Appropriate ICD therapy occurred in 24.0% of patients over a mean follow-up of 5.4 years.
  • Ejection fraction (EF) <50% (HR 2.63) was significantly associated with appropriate ICD therapy.
  • In primary prevention, atrial fibrillation (AF; HR 2.54) and EF <50% (HR 2.78) were prominent risk markers.

Conclusions:

  • ICD therapy is effective in terminating ventricular arrhythmias in HCM.
  • Atrial fibrillation (AF) history and reduced ejection fraction (EF <50%) should be considered in HCM risk stratification.
  • Conventional risk markers have weaker associations compared to AF and reduced EF.
Abstract

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
697
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
634
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
751
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
809
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
547
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
800